Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 33,900 shares, an increase of 226.0% from the September 30th total of 10,400 shares. Approximately 0.2% of the company's shares are short sold. Based on an average trading volume of 33,400 shares, the short-interest ratio is currently 1.0 days.
Institutional Trading of Theratechnologies
A hedge fund recently raised its stake in Theratechnologies stock. Cyndeo Wealth Partners LLC increased its position in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 26.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,311 shares of the company's stock after purchasing an additional 27,191 shares during the period. Cyndeo Wealth Partners LLC owned 0.29% of Theratechnologies worth $163,000 at the end of the most recent quarter.
Theratechnologies Price Performance
Shares of THTX stock traded down $0.02 on Friday, hitting $1.23. The stock had a trading volume of 33,639 shares, compared to its average volume of 45,257. The company's 50 day moving average price is $1.27 and its 200-day moving average price is $1.32. Theratechnologies has a 1 year low of $0.88 and a 1 year high of $2.58. The firm has a market capitalization of $56.56 million, a P/E ratio of -6.53 and a beta of 1.41.
Theratechnologies (NASDAQ:THTX - Get Free Report) last posted its quarterly earnings data on Thursday, October 10th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $22.60 million during the quarter. During the same period last year, the firm posted ($0.03) earnings per share. On average, equities analysts forecast that Theratechnologies will post 0.03 EPS for the current year.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
